Literature DB >> 3091354

Optimum management of asthma in pregnancy.

H Mawhinney, S L Spector.   

Abstract

In pregnancy complicated by asthma, the greatest risk to the fetus is severe and uncontrolled bronchospasm resulting in hypoxia. For this reason, the priority in management of the pregnant asthmatic should be effective control of asthma symptoms with an appropriate amount of asthma medication to accomplish this goal. In general, the management of the pregnant asthmatic does not differ greatly from that of the non-pregnant asthmatic. Virtually none of the commonly used asthma medications are totally contraindicated in pregnancy if their use is justified by the severity of the asthma in pregnancy. These include optimising non-pharmacological means of controlling symptoms, using the smallest doses of antiasthma drugs necessary to control symptoms, basing the decision to use a drug on its benefit-to-risk ratio, avoiding recently introduced drugs (for which safety in pregnancy has not been adequately established), and using the inhaled route in preference to the oral route of administration. Ideally any changes in management should be made before the anticipated pregnancy. Well-controlled asthma appears to pose little risk to either the pregnant mother or the fetus and a favourable outcome of the pregnancy should be anticipated. The patient's justifiable anxiety can often be alleviated by ensuring that she fully understands the objectives of her management and participates in it.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091354     DOI: 10.2165/00003495-198632020-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  17 in total

1.  Secretion of prednisolone into breast milk.

Authors:  S A McKenzie; J A Selley; J E Agnew
Journal:  Arch Dis Child       Date:  1975-11       Impact factor: 3.791

2.  Congenital goitre and hypothyroidism produced by maternal ingestion of iodides.

Authors:  F Carswell; M M Kerr; J H Hutchison
Journal:  Lancet       Date:  1970-06-13       Impact factor: 79.321

3.  Fetal morbidity following potentially anoxigenic obstetric conditions. VII. Bronchial asthma.

Authors:  M Gordon; K R Niswander; H Berendes; A G Kantor
Journal:  Am J Obstet Gynecol       Date:  1970-02-01       Impact factor: 8.661

4.  Asthma and pregnancy.

Authors:  A M Weinstein; B D Dubin; W K Podleski; S L Spector; R S Farr
Journal:  JAMA       Date:  1979-03-16       Impact factor: 56.272

Review 5.  The use of corticosteroids in the treatment of asthma.

Authors:  S L Spector
Journal:  Chest       Date:  1985-01       Impact factor: 9.410

6.  Placental theophylline transfer in pregnant asthmatics.

Authors:  E Labovitz; S Spector
Journal:  JAMA       Date:  1982-02-12       Impact factor: 56.272

7.  Theophylline secretion into breast milk.

Authors:  A M Yurchak; W J Jusko
Journal:  Pediatrics       Date:  1976-04       Impact factor: 7.124

8.  Advances in the treatment of bronchial asthma.

Authors:  S L Spector
Journal:  Compr Ther       Date:  1985-06

9.  Beclomethasone diproprionate for severe asthma during pregnancy.

Authors:  P A Greenberger; R Patterson
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

10.  The safety of immunotherapy during pregnancy.

Authors:  W J Metzger; E Turner; R Patterson
Journal:  J Allergy Clin Immunol       Date:  1978-04       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.